Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/8/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/8/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Status: Enrolling
Updated:  10/8/2015
Robert H. Lurie Comprehensive Cancer Center of Northwestern University Medical School
mi
from
Chicago, IL
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Status: Enrolling
Updated: 10/8/2015
Robert H. Lurie Comprehensive Cancer Center of Northwestern University Medical School
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Status: Enrolling
Updated:  10/8/2015
Sidney Kimmel Cancer Center @ Johns Hopkins
mi
from
Baltimore, MD
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Status: Enrolling
Updated: 10/8/2015
Sidney Kimmel Cancer Center @ Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Status: Enrolling
Updated:  10/8/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Status: Enrolling
Updated: 10/8/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Status: Enrolling
Updated:  10/8/2015
Weill-Cornell Medical College
mi
from
New York, NY
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Status: Enrolling
Updated: 10/8/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Status: Enrolling
Updated:  10/8/2015
The Royal Melbourne Hospital
mi
from
Parkville,
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse
Status: Enrolling
Updated: 10/8/2015
The Royal Melbourne Hospital
mi
from
Parkville,
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
California Cancer Associates for Research and Excellence
mi
from
Fresno, CA
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
California Cancer Associates for Research and Excellence
mi
from
Fresno, CA
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
Palo Verde Hematology & Oncology
mi
from
Glendale, AZ
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
Palo Verde Hematology & Oncology
mi
from
Glendale, AZ
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated:  10/8/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy
Status: Enrolling
Updated: 10/8/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated:  10/8/2015
Florida Cancer Specialists
mi
from
Fort Myers, FL
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated: 10/8/2015
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated:  10/8/2015
Northeast Georgia Medical Center
mi
from
Gainesville, GA
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated: 10/8/2015
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated:  10/8/2015
Consultants in Blood Disorders and Cancer
mi
from
Louisville, KY
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated: 10/8/2015
Consultants in Blood Disorders and Cancer
mi
from
Louisville, KY
Click here to add this to my saved trials
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated:  10/8/2015
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated: 10/8/2015
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated:  10/8/2015
Oncology Hematology Care
mi
from
Cincinnati, OH
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated: 10/8/2015
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated:  10/8/2015
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated: 10/8/2015
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated:  10/8/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients
Status: Enrolling
Updated: 10/8/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Status: Enrolling
Updated:  10/9/2015
M.D. Anderson - Orlando
mi
from
Orlando, FL
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Status: Enrolling
Updated: 10/9/2015
M.D. Anderson - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Status: Enrolling
Updated:  10/9/2015
Georgia Cancer Specialists
mi
from
Atlanta, GA
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Status: Enrolling
Updated: 10/9/2015
Georgia Cancer Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Status: Enrolling
Updated:  10/9/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Status: Enrolling
Updated: 10/9/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Status: Enrolling
Updated:  10/9/2015
University Hospital of Pennsylvania
mi
from
Philadelphi, PA
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Status: Enrolling
Updated: 10/9/2015
University Hospital of Pennsylvania
mi
from
Philadelphi, PA
Click here to add this to my saved trials
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Status: Enrolling
Updated:  10/9/2015
MD Anderson Center
mi
from
Houston, TX
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Status: Enrolling
Updated: 10/9/2015
MD Anderson Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Phase II Study of MK-2206 in Patients With Relapsed Lymphoma
Status: Enrolling
Updated:  10/9/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Phase II Study of MK-2206 in Patients With Relapsed Lymphoma
Status: Enrolling
Updated: 10/9/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
Phase I Evaluation of Interferon-alpha-1b in Solid Tumors, Lymphoma or Myeloma
Status: Enrolling
Updated:  10/11/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
Phase I Evaluation of Interferon-alpha-1b in Solid Tumors, Lymphoma or Myeloma
Status: Enrolling
Updated: 10/11/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
A Study of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy - RV-CLL-PI-0270
Status: Enrolling
Updated:  10/13/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
A Study of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy - RV-CLL-PI-0270
Status: Enrolling
Updated: 10/13/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
8-Chloro-Adenosine in Chronic Lymphocytic Leukemia
A Phase I Study of 8-Chloro-Adenosine in Previously Treated Patients With Chronic Lymphocytic Leukemia.
Status: Enrolling
Updated:  10/13/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
8-Chloro-Adenosine in Chronic Lymphocytic Leukemia
A Phase I Study of 8-Chloro-Adenosine in Previously Treated Patients With Chronic Lymphocytic Leukemia.
Status: Enrolling
Updated: 10/13/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
MBCCOP - Gulf Coast
mi
from
Mobile, AL
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
MBCCOP - Gulf Coast
mi
from
Mobile, AL
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Cedar Rapids Oncology Associates
mi
from
Cedar Rapids, IA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Cedar Rapids Oncology Associates
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
McCreery Cancer Center at Ottumwa Regional
mi
from
Ottumwa, IA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
McCreery Cancer Center at Ottumwa Regional
mi
from
Ottumwa, IA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Siouxland Hematology-Oncology Associates, LLP
mi
from
Sioux City, IA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Siouxland Hematology-Oncology Associates, LLP
mi
from
Sioux City, IA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
St. Luke's Regional Medical Center
mi
from
Sioux City, IA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
St. Luke's Regional Medical Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
CCOP - Wichita
mi
from
Wichita, KA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Green Bay Oncology, Limited - Escanaba
mi
from
Escanaba, MI
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Green Bay Oncology, Limited - Escanaba
mi
from
Escanaba, MI
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Dickinson County Healthcare System
mi
from
Iron Mountain, MI
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Dickinson County Healthcare System
mi
from
Iron Mountain, MI
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
CCOP - Kalamazoo
mi
from
Kalamazoo, MI
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
CCOP - Kalamazoo
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
CCOP - Metro-Minnesota
mi
from
St. Louis Park, MN
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
CCOP - Metro-Minnesota
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Hunterdon Regional Cancer Center at Hunterdon Medical Center
mi
from
Flemington, NJ
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Hunterdon Regional Cancer Center at Hunterdon Medical Center
mi
from
Flemington, NJ
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Warren Hospital
mi
from
Phillipsburg, NJ
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Warren Hospital
mi
from
Phillipsburg, NJ
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
Our Lady of Mercy Medical Center Comprehensive Cancer Center
mi
from
Bronx, NY
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
Our Lady of Mercy Medical Center Comprehensive Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
CCOP - Hematology-Oncology Associates of Central New York
mi
from
East Syracuse, NY
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
CCOP - Hematology-Oncology Associates of Central New York
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
St. Vincent's Comprehensive Cancer Center - Manhattan
mi
from
New York, NY
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
St. Vincent's Comprehensive Cancer Center - Manhattan
mi
from
New York, NY
Click here to add this to my saved trials
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated:  10/13/2015
CCOP - Southeast Cancer Control Consortium
mi
from
Goldsboro, NC
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma
Status: Enrolling
Updated: 10/13/2015
CCOP - Southeast Cancer Control Consortium
mi
from
Goldsboro, NC
Click here to add this to my saved trials